CN111575316A - hKLK1 recombinant plasmid, high-expression hKLK1 lentiviral particle, and construction method and application thereof - Google Patents
hKLK1 recombinant plasmid, high-expression hKLK1 lentiviral particle, and construction method and application thereof Download PDFInfo
- Publication number
- CN111575316A CN111575316A CN202010427574.2A CN202010427574A CN111575316A CN 111575316 A CN111575316 A CN 111575316A CN 202010427574 A CN202010427574 A CN 202010427574A CN 111575316 A CN111575316 A CN 111575316A
- Authority
- CN
- China
- Prior art keywords
- hklk1
- recombinant plasmid
- lentiviral particle
- constructing
- plasmid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013612 plasmid Substances 0.000 title claims abstract description 64
- 239000002245 particle Substances 0.000 title claims abstract description 40
- 238000010276 construction Methods 0.000 title abstract description 10
- 206010047470 viral myocarditis Diseases 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 241000713666 Lentivirus Species 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 19
- 206010028594 Myocardial fibrosis Diseases 0.000 claims abstract description 18
- 239000013598 vector Substances 0.000 claims abstract description 10
- 238000010367 cloning Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 31
- 238000001890 transfection Methods 0.000 claims description 18
- 238000004806 packaging method and process Methods 0.000 claims description 16
- 238000001976 enzyme digestion Methods 0.000 claims description 12
- 238000012408 PCR amplification Methods 0.000 claims description 10
- 238000001962 electrophoresis Methods 0.000 claims description 8
- 238000005520 cutting process Methods 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 108091008146 restriction endonucleases Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 239000012096 transfection reagent Substances 0.000 claims description 3
- 238000012761 co-transfection Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 238000005215 recombination Methods 0.000 abstract description 2
- 239000013613 expression plasmid Substances 0.000 abstract 1
- 102000008186 Collagen Human genes 0.000 description 19
- 108010035532 Collagen Proteins 0.000 description 19
- 229920001436 collagen Polymers 0.000 description 19
- 230000002107 myocardial effect Effects 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 9
- 239000003550 marker Substances 0.000 description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 230000004217 heart function Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000012258 culturing Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21035—Tissue kallikrein (3.4.21.35)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides an hKLK1 recombinant plasmid, a lentiviral particle with high expression level of hKLK1, a construction method and application thereof, wherein the hKLK1 recombinant plasmid is an expression plasmid for cloning hKLK1 gene, and the gene sequence of the hKLK1 recombinant plasmid is shown as SEQ ID: 1. The hKLK1 recombinant plasmid (pEZ-Lv105-hKLK1) can be used for preparing medicaments for treating viral myocarditis and myocardial fibrosis. The lentivirus is used as a vector, and the gene recombination technology is utilized to construct the lentivirus particles of high-expression hKLK1, so that the lentivirus particles are safe and nontoxic, have the function of inhibiting VMC myocardial fibrosis, can meet the use requirement, and have simple construction method, easy operation and good application prospect.
Description
Technical Field
The invention relates to a therapeutic drug for viral myocarditis, in particular to an hKLK1 recombinant plasmid for inhibiting viral myocarditis myocardial fibrosis, a lentiviral particle with high expression of hKLK1, a construction method and application thereof.
Background
Viral Myocarditis (VMC) is one of the common diseases of the cardiovascular system, and epidemiological investigations have shown that about 15-25% of VMC patients develop myocardial fibrosis and evolve into dilated cardiomyopathy, with a two-year mortality rate of up to 50%. Therefore, the inhibition of the VMC myocardial fibrosis has important significance for maintaining the cardiac structure, improving the cardiac function and reducing the fatality rate. At present, various medicines such as tranilast, carvedilol and captopril can inhibit myocardial fibrosis of VMC mice, but the clinical curative effect of the medicines is not confirmed.
According to published literature reports and clinical treatment experiences, the 3 medicines only improve the pathology of the myocardial fibrosis of the VMC mice, the improvement of the cardiac function is not obvious, and the medicines are rarely used for treating the VMC myocardial fibrosis clinically. The reasons for the above disadvantages are: the target of action of these drugs is not a critical mechanism for VMC myocardial fibrosis.
Disclosure of Invention
Based on the problems, the invention aims to provide an hKLK1 recombinant plasmid, a lentivirus particle with high expression of hKLK1, a construction method and application thereof, wherein the recombinant plasmid and the virus particle can play the roles of inhibiting VMC myocardial fibrosis and improving cardiac function, and have application prospects of being developed into medicines.
In order to achieve the purpose, the invention provides a hKLK1 recombinant plasmid which is a recombinant plasmid for cloning hKLK1 gene, and the gene sequence is shown as SEQ ID: 1.
The second aspect of the invention provides a method for constructing a recombinant plasmid of hKLK1, which is obtained by connecting the hKLK1 gene to a classical expression clone pEZ-Lv 105.
Preferably, the method for constructing the hKLK1 recombinant plasmid comprises the following steps in sequence:
(1) designing a primer for PCR amplification by taking the hKLK1 gene sequence as a template, wherein the primer is as follows:
the sequence of the upstream primer is as follows: 5'-GCGGTAGGCGTGTACGGT-3'
The sequence of the downstream primer is as follows: 5'-ATTGTGGATGAATACTGCC-3', respectively;
(2) carrying out electrophoresis on the PCR amplification product obtained in the step (1), then carrying out gel cutting recovery and purification, and carrying out enzyme cutting by using restriction enzymes BstBI and XhoI so that the two ends of the obtained hKLK1 gene sequence have BstBI and XhoI enzyme cutting sites;
(3) ligating the DNA fragment obtained in the step (2) to an pEZ-Lv105 vector;
(4) screening, recombining, cloning and enzyme digestion identification by using a PCR method.
Wherein, the PCR amplification reaction system in the step (1) comprises:
5×Buffer,5μl;
10mM dNTP,0.5μl;
20mM Mg2+,2.5μl;
template, 1. mu.l;
5pmol/L of upstream primer mfat-1-F, 0.5. mu.l;
5pmol/L downstream primer mfat-1-R, 0.5. mu.l;
5U/μl UltraPF DNA Polymerase,0.2μl;
deionized water was added to 25. mu.l.
The PCR amplification reaction procedure in the step (1) is as follows: pre-denaturing at 98 ℃ for 1min, denaturing at 98 ℃ for 10sec, annealing to 5 ℃ for 30sec, and extending at 72 ℃ at a rate of 1-4Kb/min for 7min for 25 cycles; finally, the mixture is stored at 4 ℃.
The reaction system for screening the recombinant clone by the PCR method in the step (2) comprises:
10×Taq Reaction Buffer(Mg plus),2.5μl;
10mM dNTP,0.5μl;
5U/μl Taq,0.2μl;
deionized water, 4.8. mu.l.
The PCR amplification reaction procedure in the step (2) is as follows: pre-denaturing at 94 ℃ for 5min, denaturing at 94 ℃ for 30sec, annealing to 58 ℃ for 30sec, and extending at 72 ℃ at a rate of 1Kb/min for 7min for 25 cycles; finally, the mixture is stored at 4 ℃.
The third aspect of the invention provides a lentivirus particle with high expression of hKLK1, which is obtained by connecting the recombinant plasmid of hKLK1 or the recombinant plasmid constructed by the method for constructing the recombinant plasmid of hKLK1 into lentivirus. Preferably, the administration mode is one-time intravenous injection and is based on HIV framework slow virus packaging plasmid Lenti-PacTM。
The fourth aspect of the invention provides a method for constructing a lentivirus particle with high expression of hKLK1, which comprises the following steps in sequence:
(1) Lenti-Pac lentivirus packaging plasmidTMPackaging the hKLK1 recombinant plasmid;
(2) and (4) measuring the titer.
Preferably, the step (1) adopts EndoFectinTMLenti and TiterBoostTMTransfection reagent hKLK1 recombinant plasmid and lentivirus packaging plasmid Lenti-PacTMTransfection into 293Ta cells for co-transfection, more preferably, step (1) comprises the steps of:
culturing packaging cells
② preparation of DNA-EndoFectin transfection Complex
③ transfection of packaging cells
And fourthly, harvesting the lentivirus particles.
The fifth aspect of the invention provides an application of the hKLK1 recombinant plasmid or the hKLK1 recombinant plasmid constructed by the method for constructing the hKLK1 recombinant plasmid, or the lentiviral particle with high expression of hKLK1 or the lentiviral particle with high expression of hKLK1 constructed by the method for constructing the lentiviral particle with high expression of hKLK1 in preparing a medicament for treating viral myocarditis and myocardial fibrosis.
The sixth aspect of the invention provides a medicament, which comprises the hKLK1 recombinant plasmid or the hKLK1 recombinant plasmid constructed by the method for constructing the hKLK1 recombinant plasmid, or the high-expression hKLK1 lentiviral particle constructed by the method for constructing the lentiviral particles with high expression hKLK1 or the lentiviral particles with high expression hKLK1, and a medicament vector. Wherein the drug carrier is acceptable in drug preparation. The medicament can be prepared into clinically acceptable dosage forms by preparing the hKLK1 recombinant plasmid or the hKLK1 recombinant plasmid virus particles, a medicament carrier and conventional auxiliary materials according to a conventional process.
Human tissue kallikrein 1 (hKLK 1) is a serine protein kinase and belongs to one of the active ingredients of the kallikrein-kinin system (KKS). The invention adopts a gene therapy method, utilizes the virus particles to bring the hKLK1 gene into a VMC mouse body, compared with a control group mouse, the collagen fibers proliferated in a mouse myocardial interstitial matrix are obviously reduced, the proliferation of the myocardial collagen fibers is obviously light, the ratio of I/III collagen is obviously reduced, the expression of transforming growth factor beta1 (TGF-beta 1) in the myocardium is obviously reduced, and the hKLK1 can play the roles of inhibiting the VMC myocardial fibrosis and improving the cardiac function by reducing the expression of the TGF-beta 1, thereby having the application prospect of being developed into a medicament. Because of the lack of serine protein kinase in mammals, it is necessary to introduce the hKLK1 gene into the body using a lentiviral vector or an adeno-associated viral vector.
Compared with the prior art, the hKLK1 recombinant plasmid (pEZ-Lv105-hKLK1) can be used for preparing the medicine for treating viral myocarditis and myocardial fibrosis. The lentivirus is used as a vector, and the gene recombination technology is utilized to construct the lentivirus particle (EZ. hKLK1) of the high expression hKLK1, so that the lentivirus particle is a safe and nontoxic medicine capable of inhibiting VMC myocardial fibrosis, can meet the use requirement, and has the advantages of simple construction method, easy operation and good application prospect.
Drawings
FIG. 1 is an electrophoretogram of PCR products of example 1.
FIG. 2 is an electrophoretogram of PCR products of example 1.
FIG. 3 shows the restriction identification electrophoretogram of plasmid BsrGI and AflII of pEZ-Lv105-hKLK1 from example 1.
FIG. 4 is a graph of body weight ratios of the hearts of each group of example 3.
FIG. 5 is a micrograph of the myocardial tissue morphology of each group of mice of example 3.
FIG. 6 is a graph showing the expression of type I and type III collagens in each of the myocardium of example 3.
FIG. 7 is a graph showing the expression of myocardial TGF-. beta.1 proteins of each group in example 3.
Detailed Description
To better illustrate the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to specific examples. It should be noted that the following implementation of the method is a further explanation of the present invention, and should not be taken as a limitation of the present invention.
Example 1: the gene sequence of the hKLK1 recombinant plasmid (pEZ-Lv105-hKLK1) is shown as SEQ ID:1, and the specific process is as follows:
(1) PCR amplification
Taking the gene sequence of hKLK1 as a template, designing primers for PCR amplification to ensure that the two ends of the obtained gene sequence of hKLK1 have BstBI and XhoI enzyme cutting sites, wherein the primers are as follows:
the sequence of the upstream primer is as follows: 5'-GCGGTAGGCGTGTACGGT-3'
The sequence of the downstream primer is as follows: 5'-ATTGTGGATGAATACTGCC-3', respectively;
the PCR reaction system is shown in Table 1.
TABLE 1PCR reaction System
The PCR amplification reaction program is as follows: pre-denaturing at 98 ℃ for 1min, denaturing at 98 ℃ for 10sec, annealing to 5 ℃ for 30sec, and extending at 72 ℃ at a rate of 1-4Kb/min for 7min for 25 cycles; finally, the mixture is stored at 4 ℃.
The PCR product was identified by electrophoresis, and the results are shown in FIG. 1, in which Lane 1: marker 6000; lane 2: hKLK1(800bp), the size of the DNA fragment was estimated against marker, and positive clones containing the desired fragment were selected. Using OMEGA in combinationThe Gel Extraction Kit Gel was used to recover and purify the PCR product.
(2) Enzyme digestion
The restriction enzymes BstBI and XhoI were used for digestion, and the digestion system is shown in Table 2.
TABLE 2 enzyme digestion System
Placing the reaction tube into a constant-temperature water bath kettle at 37 ℃ for incubation for more than 3h, taking out the enzyme digestion product, placing the enzyme digestion product into a water bath kettle at 80 ℃ for incubation for 20min, and inactivating the restriction enzyme; by OMEGARecovering the enzyme digestion product by using Gel Extraction Kit.
(3) Connection of
The target DNA fragment and pEZ-Lv105 vector are subjected to Fast-fusion TM reaction to obtain Fast-fusion TMCLONAse. Cloning reactions were prepared on ice as shown in table 3. mu.L of Fast-fusion (TM) clone was added to the well mixed reaction solution, the reaction tube wall was flicked to disperse the solution evenly, incubated at 25 ℃ for 15min and then stored on ice.
TABLE 3 reaction solution formulation
(4) Culturing and transforming:
1. the competent cells were removed from the-80 ℃ freezer and thawed on ice.
2. The sterilized 1.5ml centrifuge tubes were removed from the clean bench and their caps were marked with the appropriate numbers using a marker pen.
3. Mu.l of the ligation was removed using a pipette gun to the bottom of a labeled 1.5ml centrifuge tube and placed in ice.
4. The thawed competent cells were mixed well in a clean bench by pipette, 50. mu.l was added to the bottom of the 1.5ml centrifuge tube in step 3 and ice-cooled for 30min, at which time the water bath was set at 42 ℃.
5. Standing in 42 deg.C water bath, thermally shocking for 45sec, and rapidly transferring to ice box for 2-4 min.
6. The alcohol lamp was ignited on a clean bench, 400. mu.l of S.O.C medium was added by using a pipette, and then the mixture was incubated for 1 hour at 37 ℃ on a shaker at 180 rpm.
7. Taking out the converted substance from the shaking table, placing 200 μ l in an ultraclean workbench, taking 200 μ l with a pipette, spreading the converted substance uniformly, drying, placing the LB plate upside down in a 37 deg.C constant temperature incubator, and culturing for 12-16 h.
(5) Screening of recombinant clones by PCR
1. The LB plate was inverted, and the single clones on the plate were randomly selected and numbered at room temperature.
2. Each PCR tube was filled with 16. mu.l of ddH2O and 1. mu.l (5 pmol/. mu.l) of forward and reverse vector primers, and the tip was gently spotted on an LB plate, and then the tip stained with the cells was placed in the corresponding PCR tube and blown down several times.
3. The other components of the PCR were dispensed as PCR mix into each PCR tube to a total volume of 25. mu.l, then mixed well and the tube was capped, the PCR mix formulation is shown in Table 4.
TABLE 4PCR mix formulation
4. And (3) centrifuging the PCR mixture mixed with the thalli for a short time, and then placing the mixture into a PCR instrument, wherein the PCR reaction procedure is as follows: pre-denaturing at 94 ℃ for 5min, denaturing at 94 ℃ for 30sec, annealing to 58 ℃ for 30sec, and extending at 72 ℃ at a rate of 1Kb/min for 7min for 25 cycles; finally, the mixture is stored at 4 ℃.
5. The PCR product was detected by electrophoresis, and the result is shown in FIG. 2, and the size of the DNA fragment was estimated against marker, and a positive clone containing the desired fragment was selected. And wherein Lane1 is Marker 6000; lane2 is colony 1 PCR; lane3 is colony 2 PCR; lane4 is colony 3 PCR; lane5 is colony 4 PCR; lane6 is colony 5 PCR; lane6 is colony 5 PCR; lane7 was colony 6 PCR.
6. Selecting positive clones, inoculating the positive clones into 5ml LB/liquid culture medium containing antibiotics, and performing shake culture at 37 ℃ for 12-16h to prepare for extracting plasmids.
(6) Enzyme digestion identification
The restriction enzyme BsrGI was used, and the restriction system is shown in Table 5.
TABLE 5 enzyme digestion System
And (3) putting the reaction tube into a constant-temperature water bath kettle at 37 ℃ for incubation for 3h, taking out the reaction tube, putting the reaction tube into a water bath kettle at 65 ℃ or 80 ℃ for incubation for 20min, and inactivating the restriction enzyme. 0.5. mu.l of plasmid which has not been digested and 5. mu.l of the digestion product are respectively taken for electrophoresis to detect whether the digestion is complete, as shown in FIG. 3, which shows that the plasmid digestion is complete. Wherein Lane1 is Marker 6000, Lane2 is plasma ofpEZ-Lv105-hKLK1-01, Lane3 is plasma of pEZ-Lv105-hKLK1-01cut by BsrGI, Lane4 is plasma of pEZ-Lv105-hKLK1-01cut by AflII, Lane5 is Marker 3000, and Lane6 is Marker 15000. Placing the reaction tube in a 37 deg.C constant temperature water bath for over 3h, taking out enzyme digestion product, placing in 80 deg.C water bath, incubating for 20min to inactivate restriction enzyme, and treating with OMEGARecovering the enzyme digestion product by using Gel Extraction Kit.
(7) Sequencing identification
The plasmid enzyme digestion is correct, and the result is consistent with Genbank after sequencing verification. The sequencing result is correct, and the small/medium extraction kit of OMEGA endotoxin-free plasmid is used for extracting the endotoxin-free plasmid.
Example 2: construction of Lentiviral particles highly expressing hKLK1
Packaging of plasmid Lenti-Pac by lentivirusTMThe viral particles obtained after packaging the hKLK1 recombinant plasmid are based on HIV framework and are a lentivirus packaging plasmid Lenti-PacTMThe construction method comprises the following steps:
(1) culturing packaging cells
The amount of the DNA was about 1.3 × 10 two days before transfection6-1.5×106The 293Ta cells were inoculated into 10cm plates, and 10mL of 10% heat-inactivated fetal bovine serum was addedDMEM medium at 5% CO2Cells were plated and cultured at 37 ℃. For example, 293Ta cells reach 70-80% confluence on the day of transfection, and optimal packaging is relatively easy to achieve.
(2) Preparation of DNA-EndoFectin transfection Complex
To a sterile EP tube (A tube), 2.5. mu.g of hKLK1 recombinant plasmid and LentiPac were addedTMThe packaged plasmids were mixed at 5.0. mu.L (0.5. mu.g/. mu.L), and Opti-MEMI was added to make up to 200. mu.L (at this time, the total amount of plasmid in tube A was 5. mu.g). Another sterile EP tube (B tube) was added with 15. mu.L of EndoFectin Lenti transfection reagent and supplemented to 200. mu.L with Opti-MEMI. While gently swirling tube A, the solution from tube B was added dropwise to tube A (note: the order of addition was not reversed) until the addition of the solution from tube B was complete. And after the solutions are mixed, standing at room temperature for 10-25min to complete the preparation of the DNA-EndoFectin transfection compound.
(3) Transfection of packaging cells
On the day of transfection operation, taking out the cells plated and cultured in the step 1 from the incubator, and uniformly dropwise adding the transfection compound prepared in the step 2 to the cell plate; the act of sucking up the transfection complex needs to be gentle and does not repeatedly blow up the transfection complex. After the addition, the cell plate was shaken horizontally in a 8-shape (gentle motion was required) to disperse the transfection complex uniformly. After completion of transfection, at 5% CO2Culturing at 37 deg.C for 8-14 h; after 8-14h of the transfection procedure, the old medium containing the transfection complex is removed and fresh DMEM medium containing 2-5% heat-inactivated fetal calf serum, penicillin and streptomycin is added (e.g., 10mL DMEM is added to a 10cm plate). At this step, 1/500 volumes of TiterBoost may be added to fresh DMEM mediumTMTiter enhancers (e.g., 20. mu.L TiterBoost added to 10cm plates) and continued at 5% CO2And cultured at 37 ℃ to prepare for harvesting the lentiviral particles.
(4) Harvesting Lentiviral particles
Cell culture fluid is collected after 48h of transfection operation, and cell debris is removed by centrifugation at 2000 Xg for 10min, so as to obtain crude virus fluid of lentivirus.
(5) Titre determination
Chronic diseaseThe lentivirus titer obtained was determined by the virus infection titer (TCID50) method and calculated (calculation formula: 1TU ═ 100 copies of viral gene RNA), and the result showed that the virus titer was 2.4 × 108TU/ml。
Example 3: effect of Lentiviral particles (EZ. hKLK1) highly expressing hKLK1 on treating myocardial fibrosis in viral myocarditis
(1) Establishment of VMC mouse model
1. 125ml of pEZ-Lv105-hKLK1 was injected into VMC mice by tail vein injection, and the empty vector group (EZ. null) mice were injected with 125ul of empty vector (lentiviral particles incapable of expressing hKLK1) by tail vein injection, and the remaining groups (Model group, normal group (Sham)) of mice were injected with 125ul of physiological saline by tail vein injection, and the number of mice in each group was 6.
After 2.30 days, the cardiac function of the mice was examined by cardiac ultrasound.
3. Mice were sacrificed and myocardial tissue was preserved and tested for heart/body weight ratio, myocardial collagen content, myocardial collagen levels type i and type iii, and myocardial transforming growth factor beta1 (TGF-beta 1) protein expression.
(2) Results and discussion
1. Body weight ratio of heart
As shown in FIG. 4, the heart-to-weight ratio was increased in the Model group compared to the Sham group, with statistical significance of the difference (P < 0.05). Compared with the Model group, the heart weight ratio of the hKLK1 administration group (EZ. hKLK1) is reduced, the difference is statistically significant (P is less than 0.05), and the EZ.null group difference is not statistically significant (P is more than 0.05).
2. Cardiac ultrasound
As shown in Table 6, Model group mice showed an increase in both the left ventricular end-diastolic diameter (LVEDd) and the left ventricular end-systolic diameter (LVEDs) compared to the Sham group, and the calculated left ventricular Fractional Shortening (FS) and Ejection Fraction (EF) were decreased, with statistical differences (P < 0.05). Compared with the Model group, the EZ.hKLK1 group has reduced LVEDd and LVEDs, increased FS and EF, and statistically significant difference (P is less than 0.05), while the EZ.null group has no statistically significant difference (P is more than 0.05).
TABLE 6 levels of LVEDd, LVEDs, FS and EF for each group of mice
3. Myocardial collagen content determination
As shown in Table 7, the Model group showed statistically significant differences in myocardial collagen content (P < 0.05) compared to the Sham group. Compared with the Model group, the content of myocardial collagen of the EZ.hKLK1 group is obviously reduced, the difference has statistical significance (P is less than 0.05), and the content of myocardial collagen of the EZ.null group has no statistical significance (P is more than 0.05).
TABLE 7 myocardial collagen content in each group
4. Histopathological characterization of myocardium
As shown in FIG. 5, the structure of the myocardial cells of the Sham group mice is clear, the muscle fibers are arranged regularly and are connected completely without any inflammatory infiltration, necrosis and fibrosis. The Model group mice can see obvious myocardial fibrosis, part of the mice are changed like glass, the fibrotic foci are connected with cardiac muscle, and a small amount of lymphocyte infiltration can be seen. Null was essentially the same as Model group, and interstitial hyperplastic collagen fibers were significantly reduced in the ez. hklk1 group.
5. Expression of type I and type III collagen
As shown in fig. 6, after staining with sirius red, Sham group mice were shown, with a small amount of red, delicate collagen visible in the myocardial intercellular spaces; heart interstitium of a Model group mouse can see type I collagen and type III collagen, and the I collagen with large hyperplasia is overlapped repeatedly, arranged disorderly, has uneven diameter and has stronger birefringent light; the proliferation of myocardial collagen fibers of the EZ.hKLK1 group is obviously lighter than that of the Model group, and the trend of the proliferation is reduced; the ez.null mice had insignificant changes in myocardial collagen fibril proliferation compared to the Model group. The I/III collagen ratios in the Model group were significantly higher and the differences were statistically significant (P < 0.05) compared to the Model group, the I/III collagen ratios in the EZ.hKLK1 group were significantly lower and the differences were statistically significant (P < 0.05) compared to the Model group, while the I/III collagen ratios in the EZ.null group were not significantly changed and the differences were not statistically significant (P > 0.05), as shown in Table 8.
TABLE 8 collagen I/III ratio of myocardium in groups of mice
6. Expression of myocardial TGF-beta 1
As shown in FIG. 7, the expression of TGF-. beta.1 was significantly increased in the Model group compared to the Sham group, and the difference was statistically significant (P < 0.05). Compared with the Model group, the expression of TGF-beta 1 in the EZ.null group has no significant difference (P is more than 0.05), while the expression of TGF-beta 1 in the EZ.hKLK1 group is significantly reduced, and the difference has statistical significance (P is less than 0.05). In the research, the hKLK1 can play the roles of inhibiting VMC myocardial fibrosis and improving cardiac function by down-regulating the expression of TGF-beta 1, and has an application prospect of being developed into a medicament.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Sequence listing
<110> Songshan lake Central Hospital, Dongguan City (Shilong people Hospital, Dongguan city, third people Hospital, Dongguan city, cardiovascular disease institute)
<120> hKLK1 recombinant plasmid, high-expression hKLK1 lentiviral particle, and construction method and application thereof
<141>2020-05-19
<160>1
<170>SIPOSequenceListing 1.0
<210>2
<211>863
<212>DNA
<213>Artificial Sequence
<400>2
catggccaat atgattttat tttgactgat agtgacctgt tcgttgcaac aaattgatga 60
gcaatgcttt tttataatgc caactttgta caaaaaagca ggcttggaag gagttcgaac 120
catgtggttc ctggttctgt gcctcgccct gtccctgggg gggactggtg ctgcgccccc 180
gattcagtcc cggattgtgg gaggctggga gtgtgagcag cattcccagc cctggcaggc 240
ggctctgtac catttcagca ctttccagtg tgggggcatc ctggtgcacc gccagtgggt 300
gctcacagct gctcattgca tcagcgacaa ttaccagctc tggctgggtc gccacaactt 360
gtttgacgac gaaaacacag cccagtttgt tcatgtcagt gagagcttcc cacaccctgg 420
cttcaacatg agcctcctgg agaaccacac ccgccaagca gacgaggact acagccacga 480
cctcatgctg ctccgcctga cagagcctgc tgataccatc acagacgctg tgaaggtcgt 540
ggagttgccc accgaggaac ccgaagtggg gagcacctgt ttggcttccg gctggggcag 600
catcgaacca gagaatttct catttccaga tgatctccag tgtgtggacc tcaaaatcct 660
gcctaatgat gagtgcaaaa aagcccacgt ccagaaggtg acagacttca tgctgtgtgt 720
cggacacctg gaaggtggca aagacacctg tgtgggtgat tcagggggcc cgctgatgtg 780
tgatggtgtg ctccaatgtg tcacatcatg gggctacctc ccttgtggca cccccaataa 840
gccttctgtc gccttcaaag tgc 863
Claims (10)
1. The hKLK1 recombinant plasmid is characterized in that the hKLK1 gene is cloned, and the gene sequence is shown as SEQ ID: 1.
2. A method for constructing the hKLK1 recombinant plasmid according to claim 1, wherein the hKLK1 gene is ligated to a classical expression clone pEZ-Lv 105.
3. The process for constructing recombinant hKLK1 plasmid according to claim 2, which comprises the following steps in sequence:
(1) designing a primer for PCR amplification by taking the hKLK1 gene sequence as a template, wherein the primer is as follows:
the sequence of the upstream primer is as follows: 5'-GCGGTAGGCGTGTACGGT-3'
The sequence of the downstream primer is as follows: 5'-ATTGTGGATGAATACTGCC-3', respectively;
(2) carrying out electrophoresis on the PCR amplification product obtained in the step (1), then carrying out gel cutting recovery and purification, and carrying out enzyme cutting by using restriction enzymes BstBI and XhoI so that the two ends of the obtained hKLK1 gene sequence have BstBI and XhoI enzyme cutting sites;
(3) ligating the DNA fragment obtained in the step (2) to an pEZ-Lv105 vector;
(4) screening, recombining, cloning and enzyme digestion identification by using a PCR method.
4. A lentiviral particle highly expressing hKLK1, wherein the lentiviral particle is obtained by connecting the hKLK1 recombinant plasmid of claim 1 or the recombinant plasmid constructed by the method for constructing the hKLK1 recombinant plasmid of claim 2 or 3 to a lentivirus.
5. The lentiviral particle with high expression of hKLK1 according to claim 4, wherein the administration mode is intravenous injection.
6. The lentiviral particle with high expression of hKLK1 according to claim 4, which is a lentiviral packaging plasmid Lenti-Pac based on HIV frameworkTM。
7. The method for constructing the lentiviral particle highly expressing hKLK1 according to any one of claims 4 to 6, wherein the method comprises the following steps in sequence:
(1) Lenti-Pac lentivirus packaging plasmidTMPackaging the hKLK1 recombinant plasmid;
(2) and (4) measuring the titer.
8. The method for constructing high-expression hKLK1 lentivirus particles according to claim 7, wherein the method comprisesThe step (1) adopts EndoFectinTMLenti and TiterBoostTMTransfection reagent hKLK1 recombinant plasmid and lentivirus packaging plasmid Lenti-PacTMTransfection into 293Ta cells for co-transfection.
9. The use of the hKLK1 recombinant plasmid according to claim 1, or the hKLK1 recombinant plasmid constructed by the method for constructing the hKLK1 recombinant plasmid according to claim 2 or 3, or the lentiviral particle with high expression of hKLK1 according to any one of claims 4 to 6, or the lentiviral particle with high expression of hKLK1 constructed by the method for constructing the lentiviral particle with high expression of hKLK1 according to claim 7 or 8 in the preparation of a medicament for treating viral myocarditis myocardial fibrosis.
10. A medicament, comprising the hKLK1 recombinant plasmid of claim 1, or the hKLK1 recombinant plasmid constructed by the method for constructing the hKLK1 recombinant plasmid of claim 2 or 3, or the lentiviral particle with high expression of hKLK1 of any one of claims 4 to 6, or the lentiviral particle with high expression of hKLK1 constructed by the method for constructing the lentiviral particle with high expression of hKLK1 of claim 7 or 8, and a pharmaceutical carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010427574.2A CN111575316A (en) | 2020-05-19 | 2020-05-19 | hKLK1 recombinant plasmid, high-expression hKLK1 lentiviral particle, and construction method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010427574.2A CN111575316A (en) | 2020-05-19 | 2020-05-19 | hKLK1 recombinant plasmid, high-expression hKLK1 lentiviral particle, and construction method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111575316A true CN111575316A (en) | 2020-08-25 |
Family
ID=72117391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010427574.2A Pending CN111575316A (en) | 2020-05-19 | 2020-05-19 | hKLK1 recombinant plasmid, high-expression hKLK1 lentiviral particle, and construction method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111575316A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002320480A (en) * | 2000-04-20 | 2002-11-05 | Wang Shick Ryu | Recombinant hepatitis b virus plasmid vector for gene therapy |
CN1384199A (en) * | 2001-02-20 | 2002-12-11 | 深圳市人民医院 | Recombinant expression vector expressing human pancreatic tissue kallikrein gene and prepn of human pancreatic tissue kallikrein |
CN1412303A (en) * | 2001-10-18 | 2003-04-23 | 华中科技大学同济医学院附属同济医院 | Recombinant adeno-associated virus for expressing human kallikrein, preparation method and application thereof |
CN101967468A (en) * | 2007-07-02 | 2011-02-09 | 广东天普生化医药股份有限公司 | Recombinant human kallidinogenase |
-
2020
- 2020-05-19 CN CN202010427574.2A patent/CN111575316A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002320480A (en) * | 2000-04-20 | 2002-11-05 | Wang Shick Ryu | Recombinant hepatitis b virus plasmid vector for gene therapy |
CN1384199A (en) * | 2001-02-20 | 2002-12-11 | 深圳市人民医院 | Recombinant expression vector expressing human pancreatic tissue kallikrein gene and prepn of human pancreatic tissue kallikrein |
CN1412303A (en) * | 2001-10-18 | 2003-04-23 | 华中科技大学同济医学院附属同济医院 | Recombinant adeno-associated virus for expressing human kallikrein, preparation method and application thereof |
CN101967468A (en) * | 2007-07-02 | 2011-02-09 | 广东天普生化医药股份有限公司 | Recombinant human kallidinogenase |
Non-Patent Citations (7)
Title |
---|
JUN AGATA ET AL: "Kallikrein Gene Delivery Improves Cardiac Reserve and Attenuates Remodeling After Myocardial Infarction", 《HYPERTENSION》 * |
KALNINE,N.ET AL: "ACCESSION NO. BT007253,Homo sapiens kallikrein 1, renal/pancreas/salivary mRNA, complete cds", 《GENBANK》 * |
MAGNEN M ET AL: "ACCESSION NO.NM_002257.4,Homo sapiens kallikrein 1 (KLK1), mRNA", 《GENBANK》 * |
余惠珍 等: "组织激肽释放酶改善大鼠心肌重塑的实验研究", 《中国医科大学学报》 * |
刘桂林 主编: "《生物技术概论》", 30 September 2010, 中国农业大学出版社 * |
李燕 主编: "《精编分子生物学实验技术》", 30 September 2017, 世界图书出版西安有限公司 * |
高洁 等: "组织激肽释放酶与心血管重构", 《中华高血压杂志》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109678967B (en) | Targeting polypeptide for treating osteosarcoma and application thereof | |
CN115746148A (en) | Protein with coronavirus RBD and membrane fusion inhibiting polypeptide and application of protein as coronavirus inhibitor | |
CN111575316A (en) | hKLK1 recombinant plasmid, high-expression hKLK1 lentiviral particle, and construction method and application thereof | |
WO2022267086A1 (en) | Drug in mrna dosage form for treating hyperuricemia, gout or renal dysfunction, preparation method therefor, and use thereof | |
CN101444629B (en) | Non-injection gene therapy medicine and medicine box thereof | |
CN112111515A (en) | ND4 gene recombinant adeno-associated virus vector and preparation method and application thereof | |
CN110982802A (en) | Recombinant human SGK3 protein kinase hydrogel, preparation method thereof and application thereof in promoting myocardial regeneration | |
CN114517209B (en) | Circular RNA circTTC3 over-expression adeno-associated virus vector, adeno-associated virus and application thereof | |
CN114652717B (en) | Pharmaceutical application of naphazoline hydrochloride | |
CN116790612B (en) | Peroxisome germinal protein 3 for promoting myocardial regeneration and repair and application thereof | |
CN114712393B (en) | Application of Hnf-1 alpha gene modified mesenchymal stem cells in preventing and treating liver cancer | |
CN107868783A (en) | Nucleic acid molecules CTL4HSH2, its preparation method and application | |
CN107868782A (en) | Nucleic acid molecules CTL4HSH3, its preparation method and application | |
CN118121701A (en) | Use of OGDHL in preparing medicine for treating chronic heart failure | |
CN116574798A (en) | Application of piR-mmu-57256903 in preparation of medicines for preventing and treating heart diseases caused by anticancer medicines | |
CN100430412C (en) | Nucleic acid molecule RTN4BSR6 and application for preparation of anti-cancer drugs | |
CN107881171A (en) | Nucleic acid molecules CTL4HSH12, its preparation method and application | |
CN100510071C (en) | Nucleic acid molecule RTN4BSR3 and application thereof in preparing anticancer medicine | |
CN100503825C (en) | Nucleic acid molecule RTN4BSR4 and its application in preparing anticancer medicine | |
CN113755455A (en) | Oncolytic vaccinia virus carrying SIKE gene, construction method and application | |
CN107881170A (en) | Nucleic acid molecules CTL4HSH11, its preparation method and application | |
CN107955813A (en) | Nucleic acid molecules CTL4HSH14, its preparation method and application | |
CN107955811A (en) | Nucleic acid molecules CTL4HSH15, its preparation method and application | |
CN107841501A (en) | Nucleic acid molecules CTL4HSH20, its preparation method and application | |
CN107841500A (en) | Nucleic acid molecules CTL4HSH18, its preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200825 |
|
RJ01 | Rejection of invention patent application after publication |